AsianScientist (May 16, 2016) – Mundipharma has announced that they are building a BETADINE Consumer Health Hub that combines R&D, manufacturing and distribution in Singapore. The new facility will produce the equivalent of around one billion applications of the povidone-iodine-based solutions annually.
In vitro studies have shown that BETADINE targets the viruses associated with diseases including Ebola, MERS, SARS, influenza and hand, foot and mouth disease. Manufacturing BETADINE in Singapore will enable Mundipharma to respond quickly to regional health crises.
“Given the accelerating demand for essential treatments, and 70 percent of new demand projected to come from Asia, it’s critical to have a strategically positioned manufacturing capability supported by an R&D function that is dedicated to unique characteristics of the region it supports,” said president of Mundipharma Asia Pacific, Latin America, the Middle East & Africa, Mr. Raman Singh.
Singh added that there is a rising sense of responsibility in the pharmaceuticals sector to ensure that the emerging world has equal access to innovation and supply as the more mature Western economies, and Singapore is ideally placed to deliver on this goal.
Ms. Ho Weng Si, director of biomedical sciences at the Singapore Economic Development Board, said that Mundipharma’s decision to build their facility in Singapore is testament to the country’s capabilities to partner companies in both the production and development of innovative medicines to address global healthcare needs.
“The vibrant biomedical sciences ecosystem in Singapore makes it a choice location for companies to carry out manufacturing, R&D and commercial headquarters activities in one place,” Weng added.
The new factory will begin operations in January 2018.
———
Source: Mundipharma.
Disclaimer: This article does not necessarily reflect the views of AsianScientist or its staff.
